Geriatrics

Investigators find study drug was well-tolerated with no new safety concerns.

The degree of photoreceptor degeneration outside of regions of retinal pigment epithelium atrophy varied substantially between eyes with AMD.

REGENXBIO also announced the scheduling of a phase 2 trial testing RGX-314 for wet AMD.

The risk of depression or clinically relevant depressive symptoms did not significantly differ between a group taking Vitamin D and a group taking a placebo.

In a comparison with manual human grading, investigators find machine learning model produced no statically significant differences in Dice coefficients.

A team of researchers have added 3 new modifiable risk factors to a list of 9 known factors that increase the risk of developing dementia.

An expert in Alzheimer disease describes some of the struggles dementia patients might be going through during the COVID-19 pandemic.

Investigators found a 22% reduction in clinical decline at the 78-week cutoff in the intent to treat population in EMERGE who received high-dose aducanumab, with a similar reduction seen in the opportunity to complete population.

A new study has great implications for equitable access to primary care for older adults during the pandemic.

In a pair of studies, 42% of patients and care partners reported having no current treatment.

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

A perspective on what's moved virtually, and what hasn't, since the pandemic began in March.

Interim findings from a cross-sectional study shows a correlation between worse cognitive scoring and a greater rate of intravitreal injections.

A new analysis of a trio of intravitreal agents show maintained visual acuity in treatment-naive patients for at least 5 years.

The specialty is on the precipice of advancement. What gets it over the hurdle?

A large proportion of nAMD patients treated with anti-VEGF therapies continue to have active disease and fluid.

A look at how the specialty functions in telemedicine, and how it could work better with primary care physicians and endocrinologists.

How the condition affects both the vision and mindset of patients, and what clinical outcomes for anti-VEGF research do to address it.

A look at how primary care patients begin to present with diabetic retinopathy risk.

As of February, 121 unique therapies are involved in clinical trials for Alzheimer disease, with putative disease-modifying agents targeting disease onset or progression accounting for the largest number.

Cataracts and diabetic retinopathy are the 2 leading causes of acquired blindness worldwide.

It is important to understand how and why disease risk and health burden vary by socioeconomic status.

For the EMB treatment group, 65.6% of participants (n = 160) lost fewer than 15 ETDRS letters, while 86.6% (n = 103) in the ranibizumab group lost fewer than 15 ETDRS letters.

Those with ≥150 min per week in moderated or vigorous activities were low risk while those with less than 150 or sedentary activity were higher risk.

An analysis of data from a trio of phase 3 trials suggest use of the novel osteoporotic treatment could increase risk of heart attack by 18%.